| Issue Date | Title | Author(s) |
| 2022-11-30 | Assessment of the Prescriptions of Systemic Antibiotics in Primary Dental Care in Germany from 2017 to 2021: A Longitudinal Drug Utilization Study. | Gradl, G; Kieble, M; Nagaba, J; Schulz, M |
| 2018-12 | Comparing outpatient oral antibiotic use in Germany and the Netherlands from 2012 to 2016. | Gradl, G; Teichert, M; Kieble, M; Werning, J; Schulz, M |
| 2024-05 | DECLINING RATES OF FIXED-DOSE COMBINATION PILLS FOR HYPERTENSION IN GERMANY FROM 2016 TO 2023 | Goetzinger, F; Kieble, M; Laufs, U; Mahfoud, F; Schulz, M |
| 2021-10 | Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany. | Rudolph, UM; Enners, S; Kieble, M; Mahfoud, F; Böhm, M; Laufs, U; Schulz, M |
| 2018-01 | In search of a standard when analyzing medication adherence in patients with heart failure using claims data: a systematic review. | Krueger, K; Griese-Mammen, N; Schubert, I; Kieble, M; Botermann, L; Laufs, U; Kloft, C; Schulz, M |
| 2021-07-08 | Quality Appraisal of Ambulatory Oral Cephalosporin and Fluoroquinolone Use in the 16 German Federal States from 2014-2019. | Gradl, G; Werning, J; Enners, S; Kieble, M; Schulz, M |
| 2022 | Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012-2021. | Katzmann, JL; Kieble, M; Enners, S; Böhm, M; Mahfoud, F; Laufs, U; Schulz, M |
| 2022-02-27 | Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia. | Mahfoud, F; Kieble, M; Enners, S; Kintscher, U; Laufs, U; Böhm, M; Schulz, M |
| 2024-10-01 | Use of fixed-dose combinations for cardiovascular indications from 2018 to 2023: a nationwide population-based study. | Götzinger, F; Kieble, M; Daudí, AE; Kunz, M; Lauder, L; Böhm, M; Laufs, U; Mahfoud, F; Schulz, M |
| 2021-11 | Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave. | Enners, S; Gradl, G; Kieble, M; Böhm, M; Laufs, U; Schulz, M |
